This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fass, R J Search for Related Content PubMed PubMed Citation Articles by Fass, R J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1983 October; 24(4): 568-574

In vitro activity of ciprofloxacin (Bay o 9867).

R J Fass

ABSTRACT

The in vitro activities of ciprofloxacin (Bay o 9867) and seven comparative antimicrobial agents against 664 aerobic and facultatively anaerobic bacterial isolates were studied. Minimal inhibitory concentrations (MICs) of ciprofloxacin were less than or equal to 2 micrograms/ml for Enterobacteriaceae, less than or equal to 8 micrograms/ml for nonfermentative gram-negative bacilli, less than or equal to 4 micrograms/ml for gram-positive cocci, less than or equal to 0.03 micrograms/ml for Aeromonas hydrophila and Pasteurella multocida, and less than or equal to 1 microgram/ml for Listeria monocytogenes. MICs for multi-drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa were less than or equal to 4 micrograms/ml. Ciprofloxacin MICs were consistently 0 to 4 (usually 2 to 3) dilution steps lower than those of a related drug, norfloxacin (P less than 0.0001). For most species, they were lower than MICs of cefotaxime, aztreonam, theinamycin, mezlocillin, trimethoprim-sulfamethoxazole, and amikacin. With all eight drugs, increasing the inoculum size by 100-fold had a variable effect on MICs which was species related. Ciprofloxacin is a potent broad-spectrum new antimicrobial agent.

---

Antimicrob Agents Chemother. 1983 October; 24(4): 568-574

This article has been cited by other articles:

• Mizunaga, S., Kamiyama, T., Fukuda, Y., Takahata, M., Mitsuyama, J. (2005). Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems. J Antimicrob Chemother 56: 91-96 [Abstract] [Full Text]  
• Winner, J. S, Gentry, C. A, Machado, L. J, Cornea, P. (2003). Aztreonam Treatment of Pasteurella multocida Cellulitis and Bacteremia. The Annals of Pharmacotherapy 37: 392-394 [Abstract] [Full Text]  
• Gross, R. D., Hoffman, R. O., Lindsay, R. N. (1997). A Comparison of Ciprofloxacin and Tobramycin in Bacterial Conjunctivtis in Children. CLIN PEDIATR 36: 435-444 [Abstract]  
• Paker, G. E., Graham, J. A., Rauch, A. M., Collins, J. J. (1994). Cefuroxime Axetil in the Treatment of Sinusitis: A Review. Arch Fam Med 3: 165-175 [Abstract]  
• Stevens, S. X., Fouraker, B. D., Jensen, H. G. (1991). Intraocular Safety of Ciprofloxacin. Arch Ophthalmol 109: 1737-1743 [Abstract]  
• Gentry, L. O., Ramirez-Ronda, C. H., Rodriguez-Noriega, E., Thadepalli, H., del Rosal, P. L., Ramirez, C. (1989). Oral Ciprofloxacin vs Parenteral Cefotaxime in the Treatment of Difficult Skin and Skin Structure Infections: A Multicenter Trial. Arch Intern Med 149: 2579-2583 [Abstract]  
• Muder, R. R., Yu, V. L., Dummer, J. S., Vinson, C., Lumish, R. M. (1987). Infections Caused by Pseudomonas maltophilia: Expanding Clinical Spectrum. Arch Intern Med 147: 1672-1674 [Abstract]  
• FASS, R. J. (1985). The Quinolones. ANN INTERN MED 102: 400-402 [Abstract]